Needham Maintains Buy Rating on Biogen, Raises Target to $290
Needham raised its Biogen price target to $290 per share from $256 while maintaining its Buy rating.
Related stories
Newsmax to Report Third-Quarter 2026 Results
M impact | EQUITY | Oct 29, 2026, 08:09 PM UTC
Viasat Schedules Fiscal Q2 2027 Results Call for November 5
Viasat scheduled a conference call and webcast for its second-quarter fiscal 2027 financial results on November 5, 2026.
M impact | EQUITY | Oct 29, 2026, 08:09 PM UTC
Amazon Expects Q4 2026 Advertising Revenue Growth in High Teens
Amazon expects advertising revenue to grow in the high teens year over year in Q4 2026.
M impact | EQUITY | Oct 29, 2026, 08:09 PM UTC
Coveo Solutions Issues Q3 Revenue Outlook
M impact | EQUITY | Oct 29, 2026, 08:09 PM UTC
Amazon shares fall 9.76% to $220 in extended trading
Amazon shares fell 9.76% to $220.00 in extended trading following results and outlook.
M impact | EQUITY | Oct 29, 2026, 08:09 PM UTC
SkyWest Q3 2026 Results Hit by Higher Fuel Costs in Prorate Business
SkyWest said higher fuel cost per gallon in its prorate business negatively impacted Q3 2026 financial results versus Q3 2025 and Q2 2026.
M impact | EQUITY | Oct 29, 2026, 08:08 PM UTC